Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics, Inc. - Common Stock
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
What 9 Analyst Ratings Have To Say About Karuna Therapeutics
↗
September 28, 2023
Via
Benzinga
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
September 28, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Analyst Expectations for Karuna Therapeutics's Future
↗
September 08, 2023
Via
Benzinga
Karuna Therapeutics to Present at Upcoming Investor Conferences
August 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
10 Analysts Have This to Say About Karuna Therapeutics
↗
August 22, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
↗
August 04, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
↗
July 13, 2023
Via
Benzinga
Where Karuna Therapeutics Stands With Analysts
↗
June 01, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
↗
May 16, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
↗
August 22, 2023
Via
Benzinga
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Leadership Appointments
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics's Return On Capital Employed Overview
↗
May 12, 2023
Via
Benzinga
3 Biotech Buyout Targets to Watch
↗
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023
↗
July 20, 2023
Via
Benzinga
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
July 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Why Shares of Karuna Therapeutics Were Up Wednesday
↗
March 22, 2023
The clinical-stage biotech announced positive trial results for its lead therapy.
Via
The Motley Fool
What Are Latest Investor Thoughts On Karuna Therapeutics? Analyst Sees Buying Opportunity
↗
July 14, 2023
William Blair notes increasing investor inbounds on Karuna Therapeutics Inc (NASDAQ: KRTX) given the recent pullback, as the stock is down 13% off June 2023 highs and 25% off 52-week highs
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
July 06, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
June 29, 2023
Via
Benzinga
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
May 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
↗
May 09, 2023
Via
Benzinga
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
May 04, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
↗
April 28, 2023
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) released its results for the year ended December 31, 2022, revealing revenue of $15.6 million, a decrease of 10.2% compared to $17.4 million in 2021....
Via
Benzinga
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
April 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
March 24, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
March 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
March 22, 2023
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
